Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Cadisegliatin 800 mg QDDrug: Cadisegliatin 800 mg BIDDrug: Placebo
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT06334133
- Locations
- 🇺🇸
Advanced Metabolic Care & Research Institute, Inc. (AMCR), Escondido, California, United States
🇺🇸Scripps Whittier Diabetes Institute, La Jolla, California, United States
🇺🇸Denver Endocrinology Diabetes and Thyroid Center, Englewood, Colorado, United States
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 43
- Registration Number
- NCT03980730
- Locations
- 🇺🇸
Tucson Neuroscience Research, Tucson, Arizona, United States
🇺🇸Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States
🇺🇸JEM Research Institute, Atlantis, Florida, United States
Evaluation of TTP399 in Patients With Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 115
- Registration Number
- NCT03335371
- Locations
- 🇺🇸
USC Westside Center for Diabetes, Beverly Hills, California, United States
🇺🇸AMCR Institute, Escondido, California, United States
🇺🇸University of Colorado Barbara Davis Center, Aurora, Colorado, United States
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 297
- Registration Number
- NCT02916056
A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes
- First Posted Date
- 2016-01-12
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- vTv Therapeutics
- Target Recruit Count
- 174
- Registration Number
- NCT02653599
- Prev
- 1
- 2
- 3
- Next
News
RAGE Inhibitor Pipeline Shows Promise for Inflammatory Diseases with 5+ Companies Advancing Novel Therapeutics
A comprehensive pipeline analysis reveals over five companies developing RAGE inhibitors across multiple clinical stages, with promising applications in chronic inflammatory diseases and neurodegenerative disorders.
Diabetes Pipeline Shows Robust Growth with 200+ Companies Developing Novel Therapies
DelveInsight's 2025 report reveals over 200 companies are actively developing more than 200 pipeline therapies for diabetes treatment, indicating a highly competitive and innovative landscape.
FDA Lifts Clinical Hold on vTv Therapeutics' Cadisegliatin for Type 1 Diabetes
FDA has lifted the clinical hold on vTv Therapeutics' cadisegliatin program, allowing the CATT1 Phase 3 trial for type 1 diabetes to resume after addressing concerns about a chromatographic signal.